Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00331695 |
Recruitment Status :
Completed
First Posted : May 31, 2006
Last Update Posted : May 9, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
To demonstrate that the intramuscular administration of 17 alpha hydroxyprogesterones caproate allows to reduce the risk of preterm delivery, in 3 high risk populations defined by the association of an ultrasonographic cervical length egal and inferiority 26 mm between 20 and 32 weeks of gestation and:
- either a first episode of preterm labor stopped by acute tocolysis;
- either a history of late miscarriage or premature delivery or uterine malformation or DES
- either a twin pregnancy. Therefore, a randomised, multicentre trial has been designed with initial stratification according to these three risk groups, opened with two parallel arms.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Preterm Delivery | Drug: 17 alpha-hydroxyprogesterones caproate | Phase 4 |
Objective
To demonstrate that the intramuscular administration of 17 alpha - hydroxyprogesterones caproate allows to reduce the risk of preterm delivery, in 3 high risk populations defined by the association of an ultrasonographic cervical length 26 mm between 20 and 32 weeks of gestation and:
- either a first episode of preterm labor stopped by acute tocolysis;
- either a history of late miscarriage or premature delivery or uterine malformation or DES
- either a twin pregnancy. Experimental design Prospective, randomized, multicenter, trial with initial stratification according to three risk groups, opened with two parallel arms.
The maximal duration for treatment will be 16 weeks for each included patient. The duration for inclusions will be 30 months. The duration for participation of each patient will be 10 to 22 weeks. The foreseen inclusion period for this trial is from 06/01/2006 to 12/31/2008 Description Two therapeutic strategies will be compared in each risk group and attributed by uniform randomisation.
Arm A :IM injection of 17 alpha hydroxyprogesterones caproate, 500 mg, twice a week until 36 W or until preterm delivery in high risk symptomatic group and high risk twin pregnancies group.
IM injection of 17 alpha-hydroxyprogesterones caproate, 500 mg, once a week until 36 W or until preterm delivery in high risk asymptomatic group.
Arm B :No treatment with 17 alpha-hydroxyprogesterones caproate. (usual management) Presentation : Progesterone retard Pharlon 500 mg Tolerance criteria
- nausea,vomiting,
- weakness
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 560 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evaluation of the Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery |
Study Start Date : | June 2006 |
Actual Primary Completion Date : | May 2010 |
Actual Study Completion Date : | May 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
17 alpha-hydroxyprogesterones caproate
|
Drug: 17 alpha-hydroxyprogesterones caproate
17 alpha-hydroxyprogesterones caproate |
- Interval between inclusion and delivery. [ Time Frame: during de study ]Interval between inclusion and delivery.
- Preterm delivery rate < 37 W, < 34 W et < 32 W, [ Time Frame: during the study ]Preterm delivery rate < 37 W, < 34 W et < 32 W,
- Number of hospitalizations for preterm labor, [ Time Frame: during the study ]Number of hospitalizations for preterm labor,
- Cerclage performed at or after 20 weeks, [ Time Frame: during the study ]Cerclage performed at or after 20 weeks,
- Neonatal weight, [ Time Frame: during the study ]Neonatal weight,
- NICU transport [ Time Frame: during the study ]NICU transport
- Respiratory distress syndrome, [ Time Frame: during the study ]Respiratory distress syndrome,
- Bronchopulmonary dysplasia, [ Time Frame: during the study ]Bronchopulmonary dysplasia,
- Necrotizing enterocolitis, [ Time Frame: during the study ]Necrotizing enterocolitis,
- leucomalacia, [ Time Frame: during the study ]leucomalacia,
- neonatal death. [ Time Frame: during the study ]neonatal death.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 49 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ultrasonographic cervical length 26 mm between 20 and 32 weeks of gestation and:
- either a first episode of preterm labor stopped by acute tocolysis
- either a history of late miscarriage or premature delivery or uterine malformation or DES;
- either a twin pregnancy.
Exclusion Criteria:
- cervical dilatation > 3 cm,
- chorioamnionitis,
- fetal distress,
- placenta praevia,
- abruptio placenta,
- preterm premature rupture of membranes,
- polyhydramnios,
- Twin-twin transfusion syndrome,
- IUGR,
- preeclampsia or hypertension,
- other pathology justifying a preterm delivery,
- epilepsy drugs
- participation to another therapeutic trial,
- any patient for whom informed consent cannot be obtained.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00331695
France | |
CHI Poissy st Germain | |
Poissy, France, 78303 | |
Chi Poissy St Germain | |
Poissy, France, 78 |
Principal Investigator: | Patrick ROZENBERG, MD, | Assistance Publique - Hôpitaux de Paris |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Christophe AUCAN, Department of Clinical Research of developpement |
ClinicalTrials.gov Identifier: | NCT00331695 |
Other Study ID Numbers: |
P040438 |
First Posted: | May 31, 2006 Key Record Dates |
Last Update Posted: | May 9, 2011 |
Last Verified: | March 2007 |
Progesterone Preterm delivery Preterm labor Cervical length ultrasonography |
Premature Birth Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications 17 alpha-Hydroxyprogesterone Caproate 11-hydroxyprogesterone |
Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Progestins Hormones |